These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23829813)

  • 1. Effect of active hexose-correlated compound in women receiving adjuvant chemotherapy for breast cancer: a retrospective study.
    Hangai S; Iwase S; Kawaguchi T; Kogure Y; Miyaji T; Matsunaga T; Nagumo Y; Yamaguchi T
    J Altern Complement Med; 2013 Nov; 19(11):905-10. PubMed ID: 23829813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation.
    Yorulmaz A; Dogan M; Artuz F; Zengin N
    Cutan Ocul Toxicol; 2017 Jun; 36(2):135-139. PubMed ID: 27086693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
    Eckhoff L; Nielsen M; Moeller S; Knoop A
    Acta Oncol; 2011 Oct; 50(7):1075-82. PubMed ID: 21824038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
    Yanagimoto H; Satoi S; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Michiura T; Inoue K; Matsui Y; Tsuta K; Kon M
    Nutr Cancer; 2016; 68(2):234-40. PubMed ID: 26847832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
    Manso L; Moreno Antón F; Izarzugaza Perón Y; Delgado Mingorance JI; Borrega García P; Echarri González MJ; Martínez-Jañez N; López-González A; Olier Garate C; Ballesteros García A; Chacón López-Muñíz I; Ciruelos Gil E; García-Sáenz JA; Paz-Ares L
    Breast J; 2019 Mar; 25(2):219-225. PubMed ID: 30734437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials.
    Shao N; Wang S; Yao C; Xu X; Zhang Y; Zhang Y; Lin Y
    Breast; 2012 Jun; 21(3):389-93. PubMed ID: 22542064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amenorrhea, fertility preservation, and counseling among young women treated with anthracyclines and taxanes for early-stage breast cancer, a retrospective study.
    Abdel-Razeq HN; Mansour RA; Ammar KS; Abdel-Razeq RH; Zureigat HY; Yousef LM; Shahin OA
    Medicine (Baltimore); 2020 Mar; 99(11):e19566. PubMed ID: 32176115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes.
    Davis AL; Klitus M; Mintzer DM
    Clin Breast Cancer; 2005 Dec; 6(5):421-4. PubMed ID: 16381625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.
    Drooger JC; Heemskerk-Gerritsen BAM; Smallenbroek N; Epskamp C; Seynaeve CM; Jager A
    Breast Cancer Res Treat; 2016 Apr; 156(3):557-566. PubMed ID: 27060914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes.
    Chan D; Yeo WL; Tiemsim Cordero M; Wong CI; Chuah B; Soo R; Tan SH; Lim SE; Goh BC; Lee SC
    Invest New Drugs; 2010 Dec; 28(6):859-65. PubMed ID: 19705063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxanes for adjuvant treatment of early breast cancer.
    Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.
    Mitchell PL; Basser R; Chipman M; Grigg A; Mansfield R; Cebon J; Davis ID; Appia F; Green M
    Ann Oncol; 2004 Apr; 15(4):585-9. PubMed ID: 15033663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer.
    Enright K; Grunfeld E; Yun L; Moineddin R; Ghannam M; Dent S; Eisen A; Trudeau M; Kaizer L; Earle C; Krzyzanowska MK
    J Oncol Pract; 2015 Mar; 11(2):126-32. PubMed ID: 25604597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort study.
    Kwok CCH; Wong WH; Chan LL; Wong SPY; Wang F; Wong MCS; Tse SLA
    Hong Kong Med J; 2022 Dec; 28(6):438-446. PubMed ID: 36261264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Response and prognosis of neoadjuvant dose-dense or standard schedule chemotherapy with anthracyclines and taxanes for Luminal B breast cancer].
    Qiu AF; Miao ZL; Ge GK; Wang CB; Bian J; Ma HY; Xu Q
    Zhonghua Yi Xue Za Zhi; 2017 Nov; 97(44):3466-3470. PubMed ID: 29275580
    [No Abstract]   [Full Text] [Related]  

  • 18. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
    Furlanetto J; Möbus V; Schneeweiss A; Rhiem K; Tesch H; Blohmer JU; Lübbe K; Untch M; Salat C; Huober J; Klare P; Schmutzler R; Couch FJ; Lederer B; Gerber B; Zahm DM; Bauerfeind I; Nekljudova V; Hanusch C; Jackisch C; Link T; Hahnen E; Loibl S; Fasching PA
    Eur J Cancer; 2021 Mar; 145():44-52. PubMed ID: 33423006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?
    Davidson A; Gelmon K
    Future Oncol; 2011 Jan; 7(1):37-55. PubMed ID: 21174537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial.
    You JS; Guo L; Huang M; Shi XL; Lin MD; Guo Z; Cao YL; Sun YZ; Xu Q; Qu WL; Liu HL; Chen JP
    Trials; 2019 Dec; 20(1):719. PubMed ID: 31831051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.